Korean drug developer Qurient said its antibody-drug conjugate candidate QP101 was selected for Korea's 2026 national new drug development program. KDDF runs the program. It will support nonclinical work needed for an IND submission.
Grant scope
QP101 was chosen under the program's nonclinical stage support category. KDDF will cover research costs required before an investigational new drug application. The national program supports projects from early discovery through Phase 2.
How QP101 works
QP101 combines a HER2-targeted antibody with two TOP1 inhibitor payloads and two CDK7 inhibitor payloads. The two mechanisms attack cancer cells independently, while the CDK7 inhibitor blocks DNA damage repair to strengthen the TOP1 inhibitor. Qurient designed the candidate to use a lower drug-to-antibody ratio than existing HER2 ADCs.
Preclinical data
In mouse trials using 28 HER2-positive solid tumor models, QP101 posted a 53.6% response rate. Enhertu at the same dose reached 42.9%. In monkey studies, the highest dose of 90mg/kg produced no significant toxicity.
Qurient plans to use the support to advance QP101 for patients with Enhertu resistance. The company also signed a co-commercialization deal with Lonza in October. The agreement covers a linker-payload platform built from QP101's structure.